Upgrade to SI Premium - Free Trial

Pfizer (PFE) Reiterated at Outperform by BMO Capital Following Earnings Report

February 8, 2022 7:47 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $76.00 price target on Pfizer (NYSE: PFE), following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles